Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

Data from BASECAMP expected in Q1 2027 TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that enrollment has been completed for BASECAMP, the company’s Phase 2 clinical trial evaluating forazapadin for the treatment of […]

We haven't written up this one. Financial Post has the full story — the link below goes straight to it.

Read the original at financialpost.com →

More in Health & Medicine

More from Wednesday 30 September →